Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue Guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $65.27 -2.7%
Revenue Growth %: +3.9%
Financial Fact:
Net loss attributable to noncontrolling interest: -5M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +3.9%
Financial Fact:
Net loss attributable to noncontrolling interest: -5M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.76, $0.48 better than the analyst estimate of $2.28. Revenue for the quarter came in at $7.59 billion versus the consensus estimate of $6.81 billion.
Gilead Sciences sees FY2015 revenue of $28-29 million, versus the consensus of $28.50 million.
PRODUCT SALES SUMMARY (unaudited) (in millions) | |||||||
| Three Months Ended | |||||||
| March 31, | |||||||
| 2015 | 2014 | ||||||
| Antiviral products: | |||||||
| Harvoni – U.S. | $ | 3,016 | $ | — | |||
| Harvoni – Europe | 477 | — | |||||
| Harvoni – Other International | 86 | — | |||||
| 3,579 | — | ||||||
| Sovaldi – U.S. | 421 | 2,098 | |||||
| Sovaldi – Europe | 483 | 163 | |||||
| Sovaldi – Other International | 68 | 13 | |||||
| 972 | 2,274 | ||||||
| Truvada – U.S. | 409 | 368 | |||||
| Truvada – Europe | 301 | 323 | |||||
| Truvada – Other International | 61 | 69 | |||||
| 771 | 760 | ||||||
| Atripla – U.S. | 494 | 490 | |||||
| Atripla – Europe | 194 | 237 | |||||
| Atripla – Other International | 46 | 53 | |||||
| 734 | 780 | ||||||
| Stribild – U.S. | 282 | 187 | |||||
| Stribild – Europe | 61 | 24 | |||||
| Stribild – Other International | 13 | 4 | |||||
| 356 | 215 | ||||||
| Complera / Eviplera – U.S. | 163 | 131 | |||||
| Complera / Eviplera – Europe | 145 | 109 | |||||
| Complera / Eviplera – Other International | 12 | 11 | |||||
| 320 | 251 | ||||||
| Viread – U.S. | 100 | 81 | |||||
| Viread – Europe | 80 | 84 | |||||
| Viread – Other International | 54 | 46 | |||||
| 234 | 211 | ||||||
| Other Antiviral – U.S. | 14 | 7 | |||||
| Other Antiviral – Europe | 7 | 9 | |||||
| Other Antiviral – Other International | 1 | 2 | |||||
| 22 | 18 | ||||||
| Total antiviral products – U.S. | 4,899 | 3,362 | |||||
| Total antiviral products – Europe | 1,748 | 949 | |||||
| Total antiviral products – Other International | 341 | 198 | |||||
| 6,988 | 4,509 | ||||||
| Other products: | |||||||
| Letairis | 151 | 123 | |||||
| Ranexa | 117 | 111 | |||||
| AmBisome | 85 | 92 | |||||
| Zydelig | 26 | — | |||||
| Other | 38 | 36 | |||||
| 417 | 362 | ||||||
| Total product sales | $ | 7,405 | $ | 4,871 | |||
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- SPS Commerce (SPSC) Tops Q1 EPS by 12c
- The First Of Long Island (FLIC) Misses Q1 EPS by 3c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
